These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

392 related items for PubMed ID: 23720216

  • 1. Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy.
    Galsky MD, Moshier E, Krege S, Lin CC, Hahn N, Ecke T, Sonpavde G, Godbold J, Oh WK, Bamias A.
    Cancer; 2013 Aug 15; 119(16):3012-9. PubMed ID: 23720216
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Relationship between 6- and 9-month progression-free survival and overall survival in patients with metastatic urothelial cancer treated with first-line cisplatin-based chemotherapy.
    Galsky MD, Krege S, Lin CC, Hahn N, Ecke T, Moshier E, Sonpavde G, Godbold J, Oh WK, Bamias A.
    Cancer; 2013 Aug 15; 119(16):3020-6. PubMed ID: 23720197
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder.
    Karakiewicz PI, Shariat SF, Palapattu GS, Gilad AE, Lotan Y, Rogers CG, Vazina A, Gupta A, Bastian PJ, Perrotte P, Sagalowsky AI, Schoenberg M, Lerner SP.
    J Urol; 2006 Oct 15; 176(4 Pt 1):1354-61; discussion 1361-2. PubMed ID: 16952631
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
    Gohji K, Higuchi A, Maruyama S, Minayoshi K, Fujii A, Itoh N, Hasunuma Y, Tanaka H, Izumi T.
    Jpn J Clin Oncol; 1993 Oct 15; 23(5):291-8. PubMed ID: 7693990
    [Abstract] [Full Text] [Related]

  • 8. External validation of preoperative and postoperative nomograms for prediction of cancer-specific survival, overall survival and recurrence after robot-assisted radical cystectomy for urothelial carcinoma of the bladder.
    Al-Daghmin A, English S, Kauffman EC, Din R, Khan A, Syed JR, Sztorc J, Mehedint D, Sharif M, Shi Y, Wilding G, Guru KA.
    BJU Int; 2014 Aug 15; 114(2):253-60. PubMed ID: 24119175
    [Abstract] [Full Text] [Related]

  • 9. Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer.
    Armstrong AJ, Garrett-Mayer E, de Wit R, Tannock I, Eisenberger M.
    Clin Cancer Res; 2010 Jan 01; 16(1):203-11. PubMed ID: 20008841
    [Abstract] [Full Text] [Related]

  • 10. The effect of cystectomy, and perioperative methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy on the risk and pattern of relapse in patients with muscle invasive bladder cancer.
    Ennis RD, Petrylak DP, Singh P, Bagiella E, O'Toole KM, Benson MC, Olsson CA.
    J Urol; 2000 May 01; 163(5):1413-8. PubMed ID: 10751847
    [Abstract] [Full Text] [Related]

  • 11. Prognostic factors for metastatic urothelial carcinoma treated with cisplatin and 5-fluorouracil-based regimens.
    Lin CC, Hsu CH, Huang CY, Tsai YC, Huang KH, Cheng AL, Pu YS.
    Urology; 2007 Mar 01; 69(3):479-84. PubMed ID: 17382149
    [Abstract] [Full Text] [Related]

  • 12. Second-Line Chemotherapy for Metastatic Urothelial Carcinoma: Importance of Lymph Node-Only Metastasis as a Prognostic Factor and Construction of a Prognostic Model.
    Salah S, Lee JL, Rozzi A, Kitamura H, Matsumoto K, Srinivas S, Morales-Barrera R, Carles J, Al-Wardat R, Al-Rabi K, Maakoseh M.
    Clin Genitourin Cancer; 2016 Jun 01; 14(3):255-60. PubMed ID: 26552764
    [Abstract] [Full Text] [Related]

  • 13. Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck.
    Argiris A, Li Y, Forastiere A.
    Cancer; 2004 Nov 15; 101(10):2222-9. PubMed ID: 15452834
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The impact of gender on outcomes in patients with metastatic urothelial carcinoma.
    Haines L, Bamias A, Krege S, Lin CC, Hahn N, Ecke TH, Moshier E, Sonpavde G, Godbold J, Oh WK, Galsky MD.
    Clin Genitourin Cancer; 2013 Sep 15; 11(3):346-52. PubMed ID: 23673281
    [Abstract] [Full Text] [Related]

  • 16. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group.
    Bamias A, Aravantinos G, Deliveliotis C, Bafaloukos D, Kalofonos C, Xiros N, Zervas A, Mitropoulos D, Samantas E, Pectasides D, Papakostas P, Gika D, Kourousis C, Koutras A, Papadimitriou C, Bamias C, Kosmidis P, Dimopoulos MA, Hellenic Cooperative Oncology Group.
    J Clin Oncol; 2004 Jan 15; 22(2):220-8. PubMed ID: 14665607
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis.
    Lee SS, Lee JL, Ryu MH, Chang HM, Kim TW, Kang HJ, Kim WK, Lee JS, Kang YK.
    Jpn J Clin Oncol; 2007 Jan 15; 37(1):30-7. PubMed ID: 17272321
    [Abstract] [Full Text] [Related]

  • 19. Nomograms predicting survival of patients with unresectable or metastatic gastric cancer who receive combination cytotoxic chemotherapy as first-line treatment.
    Kim SY, Yoon MJ, Park YI, Kim MJ, Nam BH, Park SR.
    Gastric Cancer; 2018 May 15; 21(3):453-463. PubMed ID: 28828688
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.